Literature DB >> 26984186

TRPA1 mediates trigeminal neuropathic pain in mice downstream of monocytes/macrophages and oxidative stress.

Gabriela Trevisan1, Silvia Benemei2, Serena Materazzi2, Francesco De Logu2, Gaetano De Siena2, Camilla Fusi2, Mateus Fortes Rossato3, Elisabetta Coppi2, Ilaria Maddalena Marone2, Juliano Ferreira4, Pierangelo Geppetti5, Romina Nassini2.   

Abstract

Despite intense investigation, the mechanisms of the different forms of trigeminal neuropathic pain remain substantially unidentified. The transient receptor potential ankyrin 1 channel (encoded by TRPA1) has been reported to contribute to allodynia or hyperalgesia in some neuropathic pain models, including those produced by sciatic nerve constriction. However, the role of TRPA1 and the processes that cause trigeminal pain-like behaviours from nerve insult are poorly understood. The role of TRPA1, monocytes and macrophages, and oxidative stress in pain-like behaviour evoked by the constriction of the infraorbital nerve in mice were explored. C57BL/6 and wild-type (Trpa1(+/+)) mice that underwent constriction of the infraorbital nerve exhibited prolonged (20 days) non-evoked nociceptive behaviour and mechanical, cold and chemical hypersensitivity in comparison to sham-operated mice (P < 0.05-P < 0.001). Both genetic deletion of Trpa1 (Trpa1(-/-)) and pharmacological blockade (HC-030031 and A-967079) abrogated pain-like behaviours (both P < 0.001), which were abated by the antioxidant, α-lipoic acid, and the nicotinamide adenine dinucleotide phosphate oxidase inhibitor, apocynin (both P < 0.001). Nociception and hypersensitivity evoked by constriction of the infraorbital nerve was associated with intra- and perineural monocytic and macrophagic invasion and increased levels of oxidative stress by-products (hydrogen peroxide and 4-hydroxynonenal). Attenuation of monocyte/macrophage increase by systemic treatment with an antibody against the monocyte chemoattractant chemokine (C-C motif) ligand 2 (CCL2) or the macrophage-depleting agent, clodronate (both P < 0.05), was associated with reduced hydrogen peroxide and 4-hydroxynonenal perineural levels and pain-like behaviours (all P < 0.01), which were abated by perineural administration of HC-030031, α-lipoic acid or the anti-CCL2 antibody (all P < 0.001). The present findings propose that, in the constriction of the infraorbital nerve model of trigeminal neuropathic pain, pain-like behaviours are entirely mediated by the TRPA1 channel, targeted by increased oxidative stress by-products released from monocytes and macrophages clumping at the site of nerve injury.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  4-hydroxynonenal; CCL2; CION; NADPH oxidase; hydrogen peroxide

Mesh:

Substances:

Year:  2016        PMID: 26984186     DOI: 10.1093/brain/aww038

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  64 in total

1.  Crotonaldehyde-induced vascular relaxation and toxicity: Role of endothelium and transient receptor potential ankyrin-1 (TRPA1).

Authors:  L Jin; G Jagatheesan; J Lynch; L Guo; D J Conklin
Journal:  Toxicol Appl Pharmacol       Date:  2020-04-19       Impact factor: 4.219

Review 2.  Pain in ankylosing spondylitis: a neuro-immune collaboration.

Authors:  Katayoon Bidad; Eric Gracey; Kasey S Hemington; Josiane C S Mapplebeck; Karen D Davis; Robert D Inman
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

3.  Connexin 36 Mediates Orofacial Pain Hypersensitivity Through GluK2 and TRPA1.

Authors:  Qian Li; Tian-Le Ma; You-Qi Qiu; Wen-Qiang Cui; Teng Chen; Wen-Wen Zhang; Jing Wang; Qi-Liang Mao-Ying; Wen-Li Mi; Yan-Qing Wang; Yu-Xia Chu
Journal:  Neurosci Bull       Date:  2020-10-16       Impact factor: 5.203

4.  TRPA1 channel contributes to myocardial ischemia-reperfusion injury.

Authors:  Daniel J Conklin; Yiru Guo; Matthew A Nystoriak; Ganapathy Jagatheesan; Detlef Obal; Peter J Kilfoil; Joseph David Hoetker; Luping Guo; Roberto Bolli; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-08       Impact factor: 4.733

5.  The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel.

Authors:  Silvia Benemei; Francesco De Logu; Simone Li Puma; Ilaria Maddalena Marone; Elisabetta Coppi; Filippo Ugolini; Wolfgang Liedtke; Federica Pollastro; Giovanni Appendino; Pierangelo Geppetti; Serena Materazzi; Romina Nassini
Journal:  Br J Pharmacol       Date:  2017-07-20       Impact factor: 8.739

6.  Antinociception by the anti-oxidized phospholipid antibody E06.

Authors:  Milad Mohammadi; Beatrice Oehler; Jan Kloka; Corinna Martin; Alexander Brack; Robert Blum; Heike L Rittner
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

Review 7.  Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation.

Authors:  Felipe A Pinho-Ribeiro; Waldiceu A Verri; Isaac M Chiu
Journal:  Trends Immunol       Date:  2016-10-25       Impact factor: 16.687

8.  Regulatory T Cells and Their Derived Cytokine, Interleukin-35, Reduce Pain in Experimental Autoimmune Encephalomyelitis.

Authors:  Samuel S Duffy; Brooke A Keating; Chamini J Perera; Justin G Lees; Ryan S Tonkin; Preet G S Makker; Pascal Carrive; Oleg Butovsky; Gila Moalem-Taylor
Journal:  J Neurosci       Date:  2019-01-16       Impact factor: 6.167

9.  PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Authors:  Danielle N Lyons; Liping Zhang; Robert J Danaher; Craig S Miller; Karin N Westlund
Journal:  Clin J Pain       Date:  2017-12       Impact factor: 3.442

10.  Facilitation of MrgprD by TRP-A1 promotes neuropathic pain.

Authors:  Changming Wang; Leying Gu; Yonglan Ruan; Xiao Geng; Miao Xu; Niuniu Yang; Lei Yu; Yucui Jiang; Chan Zhu; Yan Yang; Yuan Zhou; Xiaowei Guan; Wenqin Luo; Qin Liu; Xinzhong Dong; Guang Yu; Lei Lan; Zongxiang Tang
Journal:  FASEB J       Date:  2018-08-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.